Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
Status:
Completed
Trial end date:
2016-03-21
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether topical ocular administration of LME636 60
mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC)
associated with acute anterior uveitis (AAU).